Skip to main content
Top
Published in: Diabetologia 5/2007

01-05-2007 | Article

Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way

Authors: A. G. Mainous III, R. Baker, R. J. Koopman, S. Saxena, V. A. Diaz, C. J. Everett, A. Majeed

Published in: Diabetologia | Issue 5/2007

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to make projections of the future diabetes burden for the adult US population based in part on the prevalence of individuals at high risk of developing diabetes.

Materials and methods

Models were created from data in the nationally representative National Health and Nutrition Examination Survey (NHANES) II mortality survey (1976–1992), the NHANES III (1988–1994) and the NHANES 1999–2002. Population models for adults (>20 years of age) from NHANES III data were fitted to known diabetes prevalence in the NHANES 1999–2002 before making future projections. We used a multivariable diabetes risk score to estimate the likelihood of diabetes incidence in 10 years. Estimates of future diabetes (diagnosed and undiagnosed) prevalence in 2011, 2021, and 2031 were made under several assumptions.

Results

Based on the multivariable diabetes risk score, the number of adults at high risk of diabetes was 38.4 million in 1991 and 49.9 million in 2001. The total diabetes burden is anticipated to be 11.5% (25.4 million) in 2011, 13.5% (32.6 million) in 2021, and 14.5% (37.7 million) in 2031. Among individuals aged 30 to 39 years old who are not currently targeted for screening according to age, the prevalence of diabetes is expected to rise from 3.7% in 2001 to 5.2% in 2031. By 2031, 20.2% of adult Hispanic individuals are expected to have diabetes.

Conclusions/interpretation

The prevalence of diabetes is projected to rise to substantially greater levels than previously estimated. Diabetes prevalence within the Hispanic community is projected to be potentially overwhelming.
Appendix
Available only for authorised users
Literature
1.
go back to reference Englegau MM, Geiss LS, Saaddine JB et al (2004) The evolving diabetes burden in the United States. Ann Intern Med 140:945–950 Englegau MM, Geiss LS, Saaddine JB et al (2004) The evolving diabetes burden in the United States. Ann Intern Med 140:945–950
2.
go back to reference Newnham A, Ryan R, Khunti K, Majeed A (2002) Prevalence of diagnosed diabetes mellitus in general practice in England and Wales, 1994 to 1998. Health Stat Q 14:5–13 Newnham A, Ryan R, Khunti K, Majeed A (2002) Prevalence of diagnosed diabetes mellitus in general practice in England and Wales, 1994 to 1998. Health Stat Q 14:5–13
3.
go back to reference Steinbrook R (2006) Facing the diabetes epidemic—mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 345:545–548CrossRef Steinbrook R (2006) Facing the diabetes epidemic—mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 345:545–548CrossRef
4.
go back to reference Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195–1200PubMedCrossRef Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195–1200PubMedCrossRef
5.
go back to reference Honeycutt AA, Boyle JP, Broglio KR et al (2003) A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manage Sci 6:155–164CrossRef Honeycutt AA, Boyle JP, Broglio KR et al (2003) A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manage Sci 6:155–164CrossRef
6.
go back to reference Helms RB (1992) Implications of population growth on prevalence of diabetes: a look at the future. Diabetes Care 15(Suppl 1):6–9PubMed Helms RB (1992) Implications of population growth on prevalence of diabetes: a look at the future. Diabetes Care 15(Suppl 1):6–9PubMed
7.
go back to reference King H, Aubert RE, Herman WH (1998) Global burden of diabetes 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef King H, Aubert RE, Herman WH (1998) Global burden of diabetes 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef
8.
go back to reference Boyle JP, Honeycutt KM, Narayan KMV et al (2001) Projection of diabetes burden and cost through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 24:1936–1940PubMedCrossRef Boyle JP, Honeycutt KM, Narayan KMV et al (2001) Projection of diabetes burden and cost through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 24:1936–1940PubMedCrossRef
9.
go back to reference Ruwaard D, Hoogenveen RT, Verkleij H, Kromhout D, Casparie AF, van derVeen EA (1993) Forecasting the number of diabetic patients in The Netherlands in 2005. Am J Public Health 83:989–995PubMedCrossRef Ruwaard D, Hoogenveen RT, Verkleij H, Kromhout D, Casparie AF, van derVeen EA (1993) Forecasting the number of diabetic patients in The Netherlands in 2005. Am J Public Health 83:989–995PubMedCrossRef
10.
go back to reference Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report (1998). NIH Publication no. 98-4083 National Institutes of Health, Bethesda Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report (1998). NIH Publication no. 98-4083 National Institutes of Health, Bethesda
11.
go back to reference Sturm R (2003) Increases in clinically severe obesity in the United States, 1986–2000. Arch Intern Med 163:2146–2148PubMedCrossRef Sturm R (2003) Increases in clinically severe obesity in the United States, 1986–2000. Arch Intern Med 163:2146–2148PubMedCrossRef
12.
go back to reference Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727PubMedCrossRef
13.
go back to reference Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen KA (2004) Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733PubMedCrossRef Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen KA (2004) Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733PubMedCrossRef
14.
go back to reference Herman WH, Smith PJ, Thompson TJ, Englegau MM, Aubert RE (1995) A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 18:382–387PubMedCrossRef Herman WH, Smith PJ, Thompson TJ, Englegau MM, Aubert RE (1995) A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 18:382–387PubMedCrossRef
15.
go back to reference Baan CA, Ruige JB, Stolk RP et al (1999) Performance of a predictive model to identify undiagnosed diabetes in a healthcare setting. Diabetes Care 22:213–219PubMedCrossRef Baan CA, Ruige JB, Stolk RP et al (1999) Performance of a predictive model to identify undiagnosed diabetes in a healthcare setting. Diabetes Care 22:213–219PubMedCrossRef
16.
go back to reference Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ (2000) Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes/Metab Res Rev 16:164–171CrossRef Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ (2000) Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes/Metab Res Rev 16:164–171CrossRef
17.
go back to reference Franciosi M, De Berardis G, Rossi MC et al (2005) Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-term Outcomes Observational) study. Diabetes Care 28:1187–1194PubMedCrossRef Franciosi M, De Berardis G, Rossi MC et al (2005) Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-term Outcomes Observational) study. Diabetes Care 28:1187–1194PubMedCrossRef
18.
go back to reference Schmidt MI, Duncan BB, Bang H et al (2005) Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 28:2013–2018PubMedCrossRef Schmidt MI, Duncan BB, Bang H et al (2005) Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 28:2013–2018PubMedCrossRef
19.
go back to reference Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731PubMedCrossRef Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731PubMedCrossRef
20.
go back to reference Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W (2003) Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 362:503–504CrossRef Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W (2003) Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 362:503–504CrossRef
21.
go back to reference Harris MI, Flegal KM, Cowie CC et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988–2004. Diabetes Care 21:518–524PubMedCrossRef Harris MI, Flegal KM, Cowie CC et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988–2004. Diabetes Care 21:518–524PubMedCrossRef
24.
go back to reference Koopman RJ, Mainous AG III, Liszka HA et al (2006) Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med 4:427–432PubMedCrossRef Koopman RJ, Mainous AG III, Liszka HA et al (2006) Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med 4:427–432PubMedCrossRef
25.
go back to reference Venkat Narayan KM, Boyle JP, Geiss LS, Saadine JB, Thompson TJ (2006) Impact of recent increase in incidence on future diabetes burden. Diabetes Care 29:2114–2116CrossRef Venkat Narayan KM, Boyle JP, Geiss LS, Saadine JB, Thompson TJ (2006) Impact of recent increase in incidence on future diabetes burden. Diabetes Care 29:2114–2116CrossRef
26.
go back to reference American Diabetes Association (2006) Standards of medical care in diabetes 2006. Diabetes Care 29:S4–S42 American Diabetes Association (2006) Standards of medical care in diabetes 2006. Diabetes Care 29:S4–S42
Metadata
Title
Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way
Authors
A. G. Mainous III
R. Baker
R. J. Koopman
S. Saxena
V. A. Diaz
C. J. Everett
A. Majeed
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0528-5

Other articles of this Issue 5/2007

Diabetologia 5/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.